步長製藥(603858.SH):擬以750萬元受讓安宮牛黃丸藥品生產技術
格隆匯11月29日丨步長製藥(603858.SH)公佈,根據公司發展戰略的實際需要,豐富公司的產品,推動公司“大健康”戰略發展,公司全資子公司通化谷紅製藥有限公司(“通化谷紅”)擬以750萬元受讓長春新安藥業有限公司(“新安藥業”)擁有的安宮牛黃丸藥品生產技術。
安宮牛黃丸功能主治:清熱解毒,鎮驚開竅。用於熱病,邪入心包,高熱驚厥,神昏譫語;中風昏迷及腦炎、腦膜炎、中毒性腦病、腦出血、敗血症見上述證候者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.